2 assets in Crigler-Najjar Syndrome

Therapeutic assets addressing Crigler-Najjar Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
gnt0003 Crigler-Najjar Syndrome	Genethon	P2	CCC (53)
Imlifidase Crigler-Najjar Syndrome	Genethon	P2	CCC (53)